Boston Scientific (BSX) Expected to Release Earnings on Wednesday

Boston Scientific (NYSE:BSX) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.8280 per share and revenue of $5.3671 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Boston Scientific Stock Performance

Boston Scientific stock opened at $44.26 on Monday. The firm’s 50 day simple moving average is $47.21 and its 200-day simple moving average is $63.84. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $65.78 billion, a P/E ratio of 18.52, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58.

Boston Scientific declared that its board has authorized a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the last quarter. Ausdal Financial Partners Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at $281,000. Index Technologies Group LLC bought a new position in Boston Scientific in the 4th quarter worth $272,000. Vivaldi Capital Management LP raised its holdings in Boston Scientific by 19.4% in the 2nd quarter. Vivaldi Capital Management LP now owns 2,439 shares of the medical equipment provider’s stock worth $262,000 after acquiring an additional 396 shares during the period. Finally, First Foundation Advisors acquired a new position in Boston Scientific during the 3rd quarter worth $237,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Leerink Partners decreased their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. Bank of America dropped their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Stifel Nicolaus cut their price target on Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Finally, Jefferies Financial Group lowered their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $79.84.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.